In this article, Stacey Ramsey, Senior Manager – Microbial Applications Lab, Charles River Laboratories, discusses the modernisation of rapid microbiological methods (RMMs) and the potential of ATP-bioluminescence when testing cell-based products.
Embedded as the cornerstone of microbiological quality are processes that have remained the same for over a century, unchanged from their early beginnings. To achieve optimal detectability and considerably lower risk to patients, the traditional sterility test requires a minimum of 14 days of incubation, and sometimes even longer if the test sample renders media turbid and subculturing is required to overcome visual interference.
Until recently, there was insufficient market pressure to demand a change to the drawn-out sterility test time. Traditional sterile medicines are often aseptically manufactured, and paper-based batch records can take weeks to months for a full review, depending on the batch complexity. Since the sterility test was rarely a rate-limiter in batch release, there was little appetite to warrant change.
Rapid microbial methods (RMMs) are no longer a luxury but a necessity”
Now, it appears that pharmaceutical manufacturing has turned a corner. Not only has electronic data capture become more prevalent throughout the entire manufacturing and quality testing processes, from electronic batch records, laboratory notebooks, and automated analytical testing, but the medicines themselves are evolving.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The pharmaceutical market is also tackling more challenging therapies than it targeted before, including orphan diseases, rare cancers, and infections previously thought to be untreatable. Herein lies a new challenge: for these therapies to succeed, quality control can no longer take 14 days. Rapid microbial methods (RMMs) are no longer a luxury but a necessity.
What is a rapid microbiological method?
RMMs can be broadly categorised as either growth-based or non-growth-based. While both are often utilised, growth-based methods are more common because analysing microorganisms without replication can still present challenges regarding accurate detection. These growth-based rapid methods rely on living and actively metabolising microorganisms to produce by-products that rapid systems can analyse. A popular bioanalytical method detects for the presence of adenosine triphosphate (ATP) using bioluminescence, based on the luciferin-luciferase reaction which is commonly known to provide the characteristic glow of fireflies.
ATP-bioluminescence for t-cells
Relying on microbial metabolites to find growth faster than traditional methods is challenging because it involves differentiating these metabolites from biological drug products, which are often the solutions for dealing with these complex diseases. ATP-bioluminescence is no exception: all cells produce ATP as an energy transport molecule, whether they are microbial in nature or contained within the cell therapy itself. ATP can even be a residual molecule from the biological sources used for medicine production.
Fortunately, there are ways to set microbial ATP apart from ATP produced from these biological therapies. The following case study utilised a combination of chemical depletion and filtration. During this study, nine individual lots of donor t-cells were provided for ATP-bioluminescence baseline analysis. The purpose was to determine if sterile collections of t-cell material, populated at 5.0 x 106 cells/mL, would be identified by the method as sterile.
Each sample was individually added to broth, incubated, and then analysed for residual ATP by measuring the Relative Light Unit (RLU) produced when the luciferin-luciferase reagent is added to the sample aliquot. The study found that all samples report some elevation from the baseline of negative controls, which was approximately 50-100 RLU. The highest background lot of material was lot 5, reporting around 1,000 RLU from bioluminescence, while the lowest lot reported around only 61 RLU.
This result demonstrates that while there is some residual background from the samples, and while this can vary from donor lot to lot. The sample consistently demonstrated backgrounds that were reduced compared to control studies that do not use background-ATP mitigation steps.
Table 1: background study using donor t-cells.
Microbial detection using ATP-bioluminescence
Following this case study, the next challenge was verifying that background ATP from cell lines can be reduced using both chemical depletion and filtration, microbial ATP detection can still be achieved. This portion of the study used standard Jurkat t-cells. Microbial inocula were individually added to the sample preparations, targeting as close to 10 CFU as possible. Each microorganism was studied in five replicates each, to verify repeatability across the experiment. Compendial sterility conditions were used, shortening the incubation period to 3-, 4-, or 5-days using ATP-bioluminescence. The study used 5,000 RLU as the cutoff for when a sample was deemed negative using this method, because this was found to be well above the highest background result reported from the baseline study.
Table 2: microbial inoculations of Jurkat t-cells.
Microorganism
CFU Level
3-Day Celsis Adapt™
4-Day Celsis Adapt™
5-Day Celsis Adapt™
7-Day USP <71>
14-Day USP <71>
Staphylococcus aureus
4
5
5
5
5
5
Pseudomonas aeruginosa
6
5
5
5
5
5
Streptococcus pyogenes
19
5
5
5
5
5
Cutibacterium acnes
3
0
3
5
5
5
Clostridium sporogenes
5
5
5
5
5
5
Bacteroides fragilis
10
5
5
5
5
5
Micrococcus luteus (30-35°C)
3
5
5
5
5
5
Micrococcus luteus (20-25°C)
3
0
1
2
5
5
Bacillus subtilis
10
5
5
5
5
5
Candida albicans
8
1
1
5
5
5
Aspergillus brasiliensis
5
3
5
5
5
5
Penicillium chrysogenum
5
0
5
5
5
5
During this study, results show that slow-growing Cutibacterium acnes required at least four days to become positive, when inoculated with 3 CFU. C. acnes is important for this study because it is recognised as a slow-growing challenge for rapid microbial methods. It is a known cause of sterility test failures and a common human skin microorganism that cannot be typically recovered during routine environmental monitoring, increasing the importance of its recovery during routine sterility tests. When the samples were analysed using ATP-bioluminescence, the sample preparations were not visually turbid and could not be visually differentiated from the cellular sample.
Additionally, Micrococcus luteus was found to demonstrate delayed growth at 20-25°C conditions. This microorganism favours aerobic media but also prefers warmer incubation conditions. Therefore, a faster time-to-result was achieved for M. luteus by incubating within the 30-35°C condition, using Tryptic Soy Broth (TSB) as a third incubation condition.
Conclusions & future use-cases
not only are the [case study] results more rapid, but a bioanalytical result is produced instead of a subjective turbidity result”
The above summarised study is a case study in successfully utilising a rapid microbial method that may have been previously deemed incompatible with cell-based products. Through ingenuity and development, the background ATP from the human-cell line was adequately reduced, and microbial ATP was discernable from a sterile sample within five days. Further, while t-cells are commonly used in emerging cell therapy products. It is easy to see how the data could be broadly applied to various similar product types, including other mammalian or human cell lines. Finally, not only are the results more rapid, but a bioanalytical result is produced instead of a subjective turbidity result.
The implications of USP <73>
In February 2025, the United States Pharmacopoeia (USP) published its first chapter on the use of ATP-bioluminescence as a microbiological test for short shelf-life products, taking effect in August 2025. The implications of this publication are that the bar for the use of alternative methods is lowered for the products that could benefit from them the most, and in turn, benefits the patients who need therapies as quickly as possible. As part of the implementation, users no longer require alternative method validation, as these test methods have become known to be as reliable as their traditional counterparts.
This chapter’s publication indicates that regulators now find alternative microbiological methods to be increasingly repeatable and reliable, opening up the possibility of their wide applicability in the future.
Future projections
In a future state, the need will arise for rapid methods to be available for all types of [microbiological] products”
Rapid microbiology has come a long way in recent years. While ATP-bioluminescence has been researched and understood for decades, particularly in safety monitoring for foods and home and personal care industries, the rest of pharmaceutical manufacturing is now catching up. Modern manufacturing and data collection capabilities are shortening the time to release, and the need for rapid microbial results is ever-increasing. As manufacturing evolves, complacency must not remain the approach towards modernising the laboratory capabilities. It is through ongoing use, study, and regulatory review that new and modern methods will continue to shape the Quality Control environment.
In a future state, the need will arise for rapid methods to be available for all types of products, whether they are considered short shelf-life or not. Modernisation will drive objectivity and faster reaction times to quality events, improving the lives and meeting the ongoing needs of patients. This will be achieved when compendial status for rapid methods is granted for all pharmaceutical products, regardless of the product type, thereby providing products faster and with more accurate and objective test methods.
About the author
Stacey Ramsey is Senior Manager, Microbial Applications Lab, Charles River Laboratories.
She is a QC microbiologist with 20 years of direct laboratory experience in pharmaceutical quality control. Stacey began her career in QC and R&D microbiology with CMO, Hospira (now Pfizer), in McPherson, KS, US, working with new and modern parenteral medicines. In 2015, Stacey relocated to the Carolinas, continuing her work in contract laboratory testing. Having worked in both contract manufacturing and laboratory services, she has a broad background in laboratory testing, including environmental monitoring, aseptic processing, microbial identification, endotoxin testing, and rapid microbial detection. Stacey earned her BS in Biological Sciences from Wichita State University and Master of Science degree from Friends University, US.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.